Abstract: A joint related composition includes eggshell membrane in an amount of 7% to 15.5%; perna canaliculus in an amount of 50% to 80%; curcumin in an amount of 1% to 5%; avocado or soybean unsaponifiables in an amount of 0.5% to 5%; green tea leaf extract in an amount of 5% to 15%; or collagen in an amount of 0.2% to 3%.

Abstract: Heparin-like substances (HLS) have their structure similar with heparin, the highly sulfated glycosaminoglycan (GAGs). The polysaccharide, a product of mast cells, is isolated from animal tissues (pig intestinal mucosa, bovine lung), and owes its anticoagulant activity, activates antithrombin and proteases inhibitor. Disclosed herein are novel methods of isolation, purification and characterization of HLS from snail mucus (Achatina fulica), and its uses. This HLS can be used to develop a simple, sensitive and specific assay for its biological activities of anti-SARs-CoV-2 (COVID-19) and anti-PD-L1 on the breast cancer cell.

Abstract: Methods are described herein for identifying and providing prebiotic compositions that are optimized for the health needs of individuals.

Abstract: The invention relates to a method for constructing an obligate anaerobic Salmonella strain, the obligate anaerobic Salmonella strain constructed by using said method, and the use thereof in tumor therapy.

Abstract: A method of treating pulmonary hypertension in a subject is provided. The method comprises administering a preparation comprising ammonia oxidizing microorganisms to the subject, thereby treating the pulmonary hypertension. Related preparations, kits, and devices are also provided.

Abstract: A relay directional molecular communication method based on multiple attractants is applied in a field of molecular communication to address the inefficiency of existing technologies. The method for relay nodes is used by fixing three types of attractants, and the relay nodes only release one of the three types of attractants. By using relative priority between two attractants, nanomachines can quickly find a target. Compared with existing multi-attractant multi-relay algorithms, the method does not require many types of attractant resources due to the three types of attractants, saves a variety of the attractant resources, and still achieves an effect greater than three hop relays. It is realized that when a number of the relay nodes is certain, not only the type of attractants used can be reduced, but also the efficiency of finding the target can be maintained.

Abstract: Compositions contain at least one Staphylococcus carnosus strain, for example at least one of S. carnosus CNCM I-5398 or S. carnosus CNCM I-5400. A unit dosage form of the composition contains a prophylactically or therapeutically effective amount of the at least one Staphylococcus carnosus strain. Methods of making such compositions include adding at least one Staphylococcus carnosus strain to at least one other food component.

Abstract: Provided is a novel means for promoting proliferation of a bacterium of the genus Faecalibacterium, that is, a composition containing a bacterium of the genus Acidipropionibacterium or a processed product thereof and satisfying at least one requirement selected from the following (A) to (D): (A) the composition is a composition for promoting proliferation of a bacterium of the genus Faecalibacterium; (B) the composition is a composition for improving symptoms or conditions involving a bacterium of the genus Faecalibacterium; (C) the composition is an alternative to a saccharide that promotes proliferation of a bacterium of the genus Faecalibacterium; (D) a total content of a saccharide that promotes proliferation of a bacterium of the genus Faecalibacterium in the composition is 15 mass % or less.

Abstract: The present invention relates to probiotic bacteria of the species Klebsiella oxytoca that are used for a decolonization of multidrug resistant (MDR) Enterobacteria, such as Klebsiella pneumoniae (K. pneumoniae), from the gut of a subject. The decolonization can both be therapeutic, i.e. after colonization of the gut by the multiresistant pathogen(s), or as a preventive measure before a re-colonization of the gut, as required after antibiotic treatment.

Abstract: The present invention aims to provide means capable of improving the intestinal flora and the productivity of livestock and/or poultry, especially means for improving the weight gain, the feed conversion ratio, and the uniformity of livestock and/or poultry. The object is achieved by providing a method of improving the productivity of livestock and/or poultry, and a method of improving the intestinal flora of livestock and/or poultry, by feeding the livestock and/or poultry with a feed containing trehalose and probiotics, and providing a feed for livestock and/or poultry containing trehalose and probiotics.

Abstract: Disclosed are compositions including a probiotic combination including a strain belonging to the Lactobacillus reuteri species in association with a strain belonging to the Bifidobacterium genus selected from the species: Bifidobacterium breve or Bifidobacterium lactis. These compositions are useful in the prevention and/or treatment of acute or chronic stress-related pathological conditions selected from the group including impairment of cognitive function, insomnia, anxiety, baby blues and post-partum depression, menopausal depression, generalized anxiety disorder, major depressive disorder, panic attacks, attention deficit disorder or combinations thereof. Methods of treatment are also disclosed.

Abstract: The use of a bacterium of the species Lactobacillus salivarius in the manufacture of a food product, dietary supplement or medicament for treating cardiac dysfunction, particularly myocardial infarction, congestive heart failure, dilated cardiomyopathy or inflammatory heart disease (including endocarditis, inflammatory cardiomegaly and myocarditis) is disclosed.

Abstract: This invention relates to use of a strain of lactic acid bacteria for inhibiting the growth of methane-producing bacteria and/or archaea in the gastrointestinal tract of monogastric animals, reducing the ability of the microbiome of the gastrointestinal tract to produce methane, reducing methane production or emissions, and/or for improving feed efficiency, and/or body weight or body composition of a monogastric animal.

Abstract: The present invention relates to the cosmetic, nutraceutical and/or pharmaceutical, notably dermatological, use of a strain of Lactobacillus crispatus and/or of a composition comprising it for maintaining and/or increasing the expression of extracellular matrix molecules of the skin and/or of mucous membranes and notably for maintaining and/or increasing the biomechanical properties of healthy skin and/or healthy mucous membranes, preferentially the firmness and/or elasticity and/or density of healthy skin and/or healthy mucous membranes.

Abstract: An immune checkpoint suppressant containing as an active ingredient a mixture of (a) to (g), which are koji mold, yeast, and/or lactic acid bacterium fermentation products of: (a) barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese barnyard millet, foxtail millet, and/or proso millet; (b) mandarin orange, grape, apple, Vitis Coignetiae berry, peach, persimmon, papaya, Japanese pear, watermelon, Japanese apricot, fig, Chinese quince fruit, kabocha squash, kumquat, Yuzu, loquat fruit, apricot, jujube, chestnut, matatabi fruit, and/or Japanese plum; (c) purple sweet potato, Jerusalem artichoke, carrot, onion, sweet potato, taro, Japanese wild yarn, daikon, red turnip, great burdock, lotus root, yacon, lily bulb, arrowhead, ginger, garlic, and/or turmeric; (d) cabbage, perilla, Moms leaf, fish mint, Japanese mugwort, Sasa veitchii, and/or dandelion; (e) kelp, wakame, and/or mozuku; (f) black sesame, walnut, and/or ginkgo nut; and (g) maitake and/or shiitake mushroom.

Abstract: There is provided a retroviral RNA vector comprising a 5? cap, a transgene, a 3? long terminal repeat (LTR) and an RNA packaging sequence, wherein translation of the transgene is initiated at the 5? end of the transgene in a cap-dependent manner, and wherein the 3? LTR and the RNA packaging sequence are located 3? of the transgene. Also provided is a nucleotide sequence encoding a vector genome. In addition, there is provided a host cell, a virion and a pharmaceutical composition comprising the vector or nucleotide sequence, and the use of the vector in delivering a transgene to a cell or subject.

Abstract: A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.

Abstract: Provided is a modified reovirus, a pharmaceutical composition thereof, and a method of treating cancer using the same which not only has an excellent anticancer effect on various cancers, including rare cancers, but can also enhance the effect of cancer immunotherapy agents.

Abstract: In one embodiment, the present invention provides an anti-cancer-associated non-tumor cell agent. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell agent comprising an oncolytic virus comprising a p53 gene. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell preparation comprising a recombinant virus comprising: a first gene cassette containing a telomerase reverse transcriptase promoter, an E1A gene, an IRES sequence and an E1B gene; and a second gene cassette containing a promoter and a p53 gene.

Abstract: Assay method, comprising providing a plant capable of expressing a delta-12 desaturase, wherein said delta-12 desaturase has at least 50% total amino acid sequence identity to at least one of the sequences SEQ ID NO. 328 to 336, and/or at least 59% total amino acid sequence similarity to at least one of the sequences SEQ ID NO. 328 to 336, and wherein the plant is also capable of expressing at least one or more enzymes of unsaturated fatty acid metabolism, of which enzymes at least one is capable of using linoleic acid as a substrate, and of which enzymes at least one is supposedly connected to a plant metabolic property, growing the plant, and measuring said plant metabolic property for said plant.

Abstract: A method for treating a microbial infection, especially pneumonia, comprising administering an aqueous-ethanol extract of Thymus or Boswellia or a composition containing the extract. Aqueous-ethanol extracts of Thymus and/or Boswellia.

Abstract: Nutraceutical formulations, which could be used for scalp and hair care purposes, with enhanced organoleptie properties have elements of biological origin more particularly a herbal formulation(s).

Abstract: The present disclosure relates to a method for preparing a Gynostemma pentaphyllum leaf extract, a Gynostemma pentaphyllum leaf extract prepared by the method, and a composition for improving exercise performance capacity containing the same as an active ingredient. The Gynostemma pentaphyllum leaf extract according to the present disclosure exhibits superior effect of improving exercise performance capacity and enhancing muscle strength, endurance and physical strength. In addition, the Gynostemma pentaphyllum leaf extract according to the present disclosure has the efficacy of increasing AMPK activity, facilitating beta oxidation and facilitating glucose uptake and, thus, has superior effect of reducing body weight and body fat and preventing, alleviating or treating diabetes. Because the composition of the present disclosure is derived from a natural product, it can be used usefully and safely for drugs, foods, etc. without side effects.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating otitis media with effusion comprising a fraction of Melissa officinalis leaf extract as an effective ingredient.

Abstract: Nutraceutical formulations, used for prevention, cure, treatment and/or management of hypertension and/or associated condition(s), with enhanced organoleptic properties as monotherapy, combination and/or dual therapy. The formulations have elements of biological origin more particularly a herbal formulation(s).

Abstract: Disclosed are compositions comprising Rhamnus prinoides (GESHO) extract or fragments thereof and methods of using Gesho extract for the inhibition of biofilm formation.

Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.

Abstract: A weight loss composition including banaba leaf extract, apple fruit extract, Rhodiola root extract, zinc chelate, and magnesium chelate are described. The weight loss composition may further include gardenia fruit extract, chromium chelate, Salacia extract, berberine, inositol, or mixtures thereof. Embodiments are also directed to a bulk food product and a weight management plan, which may be used in conjunction with the weight loss composition. Embodiments are also directed to kits and methods of use for treating or preventing obesity, promoting weight loss, and improving insulin resistance.

Abstract: A traditional Chinese herbal composition for treating allergic conjunctivitis and/or allergic rhinitis is prepared from the following raw material herbals in a weight ratio: 3-7 parts of szechuan pepper, 7-13 parts of szechuan lovage rhizome, 7-13 parts of belvedere fruit, 10-15 parts of common anemarrhena rhizome, 7-13 parts of divaricate saposhnikovia root, 4-8 parts of periostracum cicadae, and 7-13 parts of great burdock achene. The traditional Chinese herbal composition has the effects of dispelling wind, clearing heat and relieving itching, and has significant effects on treating allergic conjunctivitis and allergic rhinitis.

Abstract: The present invention relates to a process for preparing a pharmaceutical preparation which is to be used for diabetes and diabetic complications treatment. The present invention also provides a method of treating diabetes and diabetic complications using Semolina. Triticum and Chickpea or the pharmaceutical preparation comprising them and the mixtures thereof. The present process is simple. economical. bio-friendly, and industrially applicable.

Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.

Abstract: This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and/or a growth hormone receptor antagonist and/or a selective estrogen receptor modulator (SERM) and/or a 2nd somatostatin receptor ligand (SRL).

Abstract: The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifiers, menthol, and an aqueous solvent, and thus exhibits excellent stability as well as ameliorating ocular irritation such as a feeling of grittiness, blurry vision, and the like.

Abstract: Compositions for peptide therapeutics of cancer are provided. Methods of using such compositions containing the same are also described, and a step of allowing the peptide therapeutics to coexist with a cancer cell to destroy the cancer cell.

Abstract: The invention relates to antibacterial compositions comprising micrococcin P1 and at least one additional antibacterial agent, which is preferably a bacteriocin or an antibiotic. The compositions may be used as an antibacterial, particularly for preventing or treating a bacterial infection.

Abstract: The present invention relates to pharmaceutical formulations comprising a therapeutically effective amount of an Annexin A1 (AnxA1) N-terminal-peptide having improved solubility and/or stability, while retaining agonistic activity at one or more of the formyl peptide receptors, including FPR1, FPR2 and FPR3.

Abstract: Methods are disclosed herein for modulating osteoclast fusion. In some embodiments, these methods include administering an effective amount of a Lupus autoantigen (La) protein, or an agent that modulates La protein expression or activity, to a subject in need thereof, thereby modulating osteoclast fusion in the subject. In some embodiments, the method increases osteoclast fusion and bone resorption. In other embodiments, the method decreases osteoclast fusion and bone resorption.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

Abstract: Embodiments of the instant disclosure relate to novel methods for treatment of one or more pathologic entities of Type 2 diabetes. In certain embodiments, methods concern reducing the risk of developing, preventing and/or treating a pathologic entity of Type 2 diabetes or other condition having a pathologic entity component by administering to a subject in need thereof a granulocyte macrophage colony stimulating factor (GM-CSF) or recombinantly produced molecule or fragment thereof, or an analog thereof. In other embodiments, methods concern decreasing pancreatic islet amyloid deposition in a subject by administering to the subject, GM-CSF or recombinantly produced molecule or fragment thereof, or an analog thereof, wherein the subject has pancreatic islet amyloid deposition.

Abstract: Methods of using IL-2 fusion proteins to treat and/or prevent transplant rejection such as heart transplant rejection are disclosed.

Abstract: Provided herein are extended release hydrogel conjugates of c-natriuretic peptides, methods of preparation thereof, and methods of use thereof.

Abstract: The present invention relates to a solid oral pharmaceutical composition comprising (i) a core comprising a GLP-1 receptor agonist, and (ii) a first coating, wherein the first coating comprises a copolymer (A) in combination with a copolymer (B) and/or a copolymer (C) and/or a copolymer (D).

Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.

Abstract: Disclosed are methods of treating pain in a mammal, which may include the step of administering human growth hormone to a mammal in need thereof. The pain treated by the disclosed methods may be of a type caused by inflammation induced mechanical and/or thermal hypersensitivity, and may include, for example, a pain type resulting from one or more conditions selected from peripheral injury pain, post-operative pain, cutaneous inflammation, cutaneous incision, muscle incision, or chronic pain. Disease states in which the disclosed methods may be used include fibromyalgia, sickle cell anemia, epidermolysis bullosa, erythromelalgia, complex regional pain syndrome, or generalized muscle pain.

Abstract: Methods of attenuating an antigenic response in a mammal to one or more Type 1 diabetes related-antigens are provided. The method may result in delaying the onset of decreased pancreatic beta cell function in the mammal and/or at least delaying a reduction in serum C-peptide levels in the mammal The method comprises sublingually administering an effective amount of an insulin-related peptide to the mammal and commonly makes use of a sublingual formulation of an insulin-related peptide that includes an aqueous pharmaceutically acceptable carrier, e.g., an aqueous carrier which comprises at least about 30 vol. % glycerin.

Abstract: The present invention provides a composition comprising a combination of polypeptides derived from collagen type VI. Also provided are pharmaceutical compositions and kits comprising the composition of the invention. Related aspects provide medical devices, implants, wound care products and materials for use in the same associated with the composition of the invention, and methods of their preparation. Also provided are methods and uses of the composition in the treatment and/or prevention of microbial infections and in wound care, and a method of killing microorganisms in vitro.

Abstract: A method for treatment of the diseases related to overexpression of tumor necrosis factor-? (TNF-?) and/or interleukin-1? (IL-1?) of a patient. The method comprises: administering a therapeutically effective dose of elapidae postsynaptic neurotoxin molecules (SEQ ID NOs. 1-21) and a pharmaceutically acceptable carrier. The diseases comprise rheumatoid arthritis, rheumatic arthritis, gouty arthritis, osteoarthritis, traumatic arthritis, ankylosing spondylitis, diabetes, diabetic peripheral neuropathy, diabetic retinopathy, systemic lupus erythematosus, neuropathic pain, cancer pains, myocarditis, pancreatic cancer, and liver cancer. The mature proteins or peptides of the elapidae postsynaptic neurotoxin molecules include any one of the amino acid sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 21, or have the homology of 70% or more to the amino acid sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 21 respectively.

Abstract: The presently disclosed subject matter describes methods of treating cocaine use disorder and organophosphorus toxicity in which a butyrylcholinesterase fusion protein is administered to a subject in need thereof.

Abstract: The present invention relates to composition comprising a clustered, regularly interspaced, short palindromic repeats (CRISPR) system comprising i) at least one CRISPR-associated protein 13 (Cas13) or a nucleotide sequence encoding said Cas13 protein fused with at least one nuclear localization signal (NLS) fused to at least one nuclear export sequence (NES) and ii) at least one guide RNA (gRNA) or a nucleotide sequence encoding said gRNA capable of hybridizing with one or more target RNA molecules.

Abstract: Citrate buffer, a polyol, a polymer, a salt, a preservative are used individually or in combination in a liquid coating or film composition with DispersinB to stabilize the DispersinB at an ambient or higher temperature. The polyol may comprise sorbitol, glycerol, propylene glycol, isomalt, erythritol, or maltitol. The polymer may comprise poloxamer 407, polyvinyl alcohol, gelatin, cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, or polyvinylpyrrolidone. The salt may comprise NaCl, Na2SO4, NH4Cl, KCl, KNO3, or K2SO4. The preservative may comprise ethylenediaminetetraacetic acid (EDTA), levulinic acid, or anisic acid.